Современные подходы к реваскуляризации бедренноподколенных поражений. Достижения и перспективы

Эндоваскулярные вмешательства доказали свою эффективность в лечении поражений бедренно-подколенного артериального сегмента. Большое количество опубликованных научных работ свидетельствует о сохраняющейся актуальности и перспективе этого направления в настоящее время. В статье представлен анализ исследований за последние 5 лет о разных способах лечения, результаты применения баллонов и стентов с цитостатическими покрытиями. Предложены пути улучшения результатов интервенционных вмешательств на бедренно-подколенном сегменте.

1. Hirsch AT, Duval S. The global pandemic of peripheral artery disease. Lancet. 2013;382:1312-14. https://doi.org/101016/S0140-6736(13)61576-7

2. Al-Nouri O, Krezalek M, Hershberger R. Failed superficial femoral artery intervention for advanced infrainguinal occlusive disease has a significant negative impact on limb salvage. J Vasc Surg. 2012;56:106-10. https://doi.org/10.1016/j.jvs.2011.10.108.

3. Fanelli F, Cannavale A, Boatta E. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012; 19(5):571-80. https://doi.org/10.1583/JEVT-12-3926MR.1.

4. Chaar, Cassius I. Ochoa. Distal embolization during lower extremity endovascular interventions. J Vasc Surg. 2017; 1:14350. https://doi.org/10.1016/j.jvs.2017.01.032.

5. De Martino RR, Hoel AW, Beck AW. Participation in the Vascular Quality Initiative is associated with improved perioperative medication use, which is associated with longer patient survival. J Vasc Surg. 2015;61(4):1010-9. https://doi.org/10.1016/j.jvs.2014.11.073.

6. Werk M, Albrecht T, Meyer DR. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831-40. https://doi.org/10.1161/CIRCINTERVENTIONS.112.971630.

7. Maleckis K, Anttila E, Aylward P, et al. Nitinol stents in the femoropopliteal artery: a mechanical perspective on material, design, and performance. Ann biomed eng. 2018; 1-21. https://doi.org/10.1007/s10439-018-1990-1.

8. Gray WA, Keirse K, Soga Y. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. The Lancet. 2018;392(10157): 1541-51. https://doi.org/10.1016/S0140-6736(18)32262-1.

9. Chowdhury MM, McLain AD, Twine CP. Angioplasty versus bare metal stenting for superficial femoral artery lesions. Cochrane Database Syst Rev. 2014;24(6). https://doi.org/10.1002/14651858.

10. Sibe M, Kaladji A, Boirat C. French multicenter experience with the GORE TIGRIS Vascular Stent in superficial femoral and popliteal arteries. J Vasc Surg. 2017;65(5):1329-35. https://doi.org/10.1016/j.jvs.2016.11.056.

11. Zhan LX, Branco BC, Armstrong DG, Mills JL. The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing. J Vasc Surg. 2015;61(4):939-44. https://doi.org/10.1016/j.jvs.2014.11.045.

12. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13): 1358-65. https://doi.org/10.1161/CIRCULATIONAHA.107.735985.

13. Fowkes FG, Rudan D, Rudan I. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-40. https://doi.org/10.1016/S0140-6736(13)61249-0.

14. Yokoi H, Ohki T, Kichikawa K. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. JACC: Cardiovasc Interv. 2016;9(3):271-7 https://doi.org/10.1016/j.jcin.2015.09.035.

15. Abola MTB, Bhatt DL, Duval S. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis. 2012;221(2):527-35. https://doi.org/10.1016/j.atherosclerosis.2012.01.002.

16. Thieme M, Lichtenberg M, Brodmann M. Lutonix 014 DCB global Below the Knee Registry Study: interim 6-month outcomes. J Cardiovasc Surg (Torino). 2018;59(2):232-6. https://doi.org/10.23736/S0021-9509.18.10269-2.

17. Bosiers IO, Nanto S, Uematsu M. Importance of the angiosome concept for endovascular therapy in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2010;75(6):830-6. https://doi.org/10.1002/ccd.22319.

18. Rabtsun A, Karpenko A, Zoloev DG. Remote Endarterectomy and Lamina Vastoadductoria Dissection Improves Superficial Femoral Artery Biomechanical Behavior during Limb Flexion. Ann Vasc Surg. 2017;50:112-8. https://doi.org/10.1016/j.avsg.2017.12.007.

19. Davaine JM, Azema L, Guyomarch B. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L’Artere femorale superficielle” cohort). Eur J Vasc Endovasc Surg. 2012;44(4):432-41. https://doi.org/10.1016/j.ejvs.2012.07015.

20. Hernigou J, Gordienco A, Dakhil B. Propionibacterium granulosum bare-metal stent infection after drug-eluting balloon. J Mal Vasc. 2015;40(4):259-64. https://doi.org/10.1016/j.jmv.2015.05.004.

21. Scheinert D, Scheinert S, Sax J. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. JACC. 2005;45(2):312-5. https://doi.org/10.1016/j.jacc.2004.11.026.

22. Kinstner CM, Lammer J, Willfort-Ehringer A. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial. JACC Cardiovasc Interv. 2016;9(13):1386-92. https://doi.org/10.1016/j.jcin.2016.04.012.

23. Shrikhande GV, Khan SZ, Hussain. Lesion types and device characteristics that predict distal embolization during percutaneous lower extremity interventions. J Vasc Surg. 2011;53(2):347-52. https://doi.org/10.1016/j.jvs.2010.09.008.

24. Cremers B, Speck U, Kaufels N. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201-6. https://doi.org/10.1160/TH08-06-0387

25. De Cock E, Sapoval M, Julia P. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France. Cardiovasc Interv Radiol. 2013;36(2):362-70. https://doi.org/10.1007/s00270-012-0494-x.

26. Thieme M, Von Bilderling P, Paetzel C. The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon. JACC: Cardiovasc Interv. 2017;10(16):1682-90. https://doi.org/10.1016/j.jcin.2017.04.041.

27. Bradbury AW, Adam DJ, Bell J. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg. 2010;51(5):18-31. https://doi.org/10.1016/j.jvs.2011.08.014.

28. Dake MD, Ansel GM, Jaff. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year followup from the Zilver PTX randomized and single-arm clinical studies. JACC. 2013;61(24):2417-27 https://doi.org/10.1016/j.jacc.2013.03.034.

29. Gerhard-Herman MD, Gornik HL, Barrett. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. JACC. 2017;69(11):1465-508. https://doi.org/10.1016/j.jacc.2016.11.007

30. Xu Y, Jia X, Zhang J. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I. JACC: Cardiovasc Interv. 2018;11(23):2347-53. https://doi.org/10.1016/j.jcin.2018.07041.

31. Kuznetsov K, Stepanova A, Kvon R. Electrospun Produced 3D Matrices for Covering of Vascular Stents: Paclitaxel Release Depending on Fiber Structure and Composition of the External Environment. Materials. 2018;11(11):2176. https://doi.org/10.3390/ma11112176.

32. Krokidis M, Spiliopoulos S, Katsanos K. Peripheral applications of drug-coated balloons: past, present and future. Cardiovasc Interv Radiol. 2013;36(2):281-91. https://doi.org/10.1007/s00270-012-0467-0.

33. Franzone A, Stabile E, Trimarco. Peripheral drug-eluting technology. Cardiol Clin. 2015;33(1): 151-62. https://doi.org/10.1016/j.ccl.2014.09.005.

34. Gostev AA, Karpenko AA, Laktionov PP. Polyurethanes in cardiovascular prosthetics. Polymer Bull. 2018;1-15. https://doi.org/10.1007/s00289-017-2266-x.

35. Dake MD, Ansel GM, Jaff MR. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-83. https://doi.org/10.1161/CIRCULATIONAHA.115.016900.

36. Tian W, Kuhlmann MT, Pelisek. Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model. J Endovasc Ther. 2006;13(5):616-29. https://doi.org/10.1583/05-1802MR.1.

37. Varcoe RL, Schouten O, Thomas SD. Experience with the absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes. JACC: Cardiovasc Interv. 2016;9(16): 1721-8. https://doi.org/10.1016/j.jcin.2016.06.005.

38. Jens S, Conijn AP, Koelemay MJW. Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 1: above the knee). Eur J Vasc Endovasc Surg. 2014;47(5):524-35. https://doi.org/10.1016/j.ejvs.2014.02.011.

39. Bisdas T, Beropoulis E. A. Argyriou 1-year all-comers analysis of the Eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty. JACC: Cardiovasc Interv. 2018;11(10):957-66. https://doi.org/10.1016/j.jcin.2018.03.046.

40. Muller-Hulsbeck S, Humme TH, Schafer JP, et al. Final results of the protected superficial femoral artery trial using the FilterWire EZ system. Cardiovasc Interv Radiol. 2010;33(6): 1120-7 https://doi.org/10.1007/s00270-010-9936-5.

41. Lam RC, Shah S, Faries PL, et al. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. J Vasc Surg. 2007;46(6):1155-9. https://doi.org/10.1016/j.jvs.2007.07.058.

42. Bosiers M, Torsello G, GiBler HM. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16(3):261-9. https://doi.org/10.1583/08-2676.1

43. Katsanos K. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7,24:e011245. https://doi.org/10.1161/JAHA.118.011245.

44. Diehm N, Schneider H. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions. J Endovasc Ther. 2013;20(6):819-25. https://doi.org/10.1583/13-4416R.1.

45. Sheng N, Chiriano J, Teruya TH. Evaluation of superficial femoral artery remote endarterectomy for treatment of critical limb ischemia in patients with limited autogenous conduit. Ann Vasc Surg. 2014;28(1):262-e1. https://doi.org/10.1016/j.avsg.2013.01.023.